Cargando…

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus

OBJECTIVES: To characterize the relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with moderate to severe SLE despite standard therapy, using pooled data from two phase 3 trials. METHODS: TULIP-1 and TULIP-2 were randomized, placebo-controlled, 52-week trials of intra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chia, Yen Lin, Zhang, Jianchun, Tummala, Raj, Rouse, Tomas, Furie, Richard A, Morand, Eric F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071514/ https://www.ncbi.nlm.nih.gov/pubmed/34528084 http://dx.doi.org/10.1093/rheumatology/keab704

Ejemplares similares

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
por: Chatham, W. Winn, et al.
Publicado: (2021)

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021)

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
por: Morand, Eric F, et al.
Publicado: (2018)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Bruce, Ian N, et al.
Publicado: (2022)

Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023)

Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
por: Liu, Zhihui, et al.
Publicado: (2022)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Ballew, Nick, et al.
Publicado: (2022)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019)

Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review
por: Khan, Muhammad Atif, et al.
Publicado: (2023)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials
por: Stull, Donald, et al.
Publicado: (2022)

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
por: Neupane, Binod, et al.
Publicado: (2023)

OA14 The role of anifrolumab in treating life threatening systemic lupus erythematosus with severe mucocutaneous involvement
por: Baldwin, Christopher, et al.
Publicado: (2023)

Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature
por: Paolino, Giovanni, et al.
Publicado: (2023)

Alopecia secondary to severe discoid lupus responding to anifrolumab
por: Han, Shannon, et al.
Publicado: (2023)

What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
por: Furie, Richard, et al.
Publicado: (2021)

Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases
por: Kowalski, Eric H., et al.
Publicado: (2023)

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
por: Loncharich, Michael F., et al.
Publicado: (2022)

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Editorial: Focus on Systemic Lupus Erythematosus
por: Harris, James, et al.
Publicado: (2016)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Long-term anifrolumab safe in SLE
por: McHugh, Jessica
Publicado: (2023)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
por: Cortés-Hernández, Josefina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9n8ac5qvh36uldeglvrieo83e0